Current position

Ray Dalio’s Idexx Labs Inc (IDXX) position

Reported position history, portfolio importance and verified filing changes from public SEC disclosures.

Bridgewater Associates, LPVerified through Q2 2026
Relationship snapshot

At a glance

The full verified relationship, including prior ownership episodes and exits where supported.

First reportedQ2 2010Earliest verified positive filing snapshot
Latest statusCurrent positionBased on the latest supported relationship state
Peak shares144.17KHighest verified quarter-end share count
Quarters reported35Verified quarters with shares above zero
What happened?

Bridgewater Associates, LP first reported Idexx Labs Inc in Q2 2010. After an earlier exit, the position later appeared again in a verified filing. The reported position was increased and reduced across later filings. Bridgewater Associates, LP currently reports 33.53K shares. The latest verified filing showed: Bought 225.1% more.

Verified SEC history

Position over time

See the same verified relationship through reported shares, portfolio weight or reported value.

Metric

Gaps indicate periods that cannot be safely connected or where a verified corporate action changes the raw share scale. Stock price, when available, is market context and not a transaction price.

Key filing events

What changed

Latest filing plus the most meaningful reported changes. Unchanged quarters are collapsed by default.

Q2 2026
Bought 225.1% more+23.21K shares · 33.53K shares reported after the change
Filing context

Quarter-end price $526.44 · Estimated holding basis $544.75

Q1 2026
Bought 67.5% more+4.16K shares · 10.31K shares reported after the change
Filing context

Quarter-end price $561.89 · Estimated holding basis $585.97

Q4 2025
Sold 16.8% of the position−1.25K shares · 6.16K shares remained
Filing context

Quarter-end price $676.53 · Estimated holding basis $602.22

Q3 2025
Bought 182.1% more+4.78K shares · 7.40K shares reported after the change
Filing context

Quarter-end price $638.89 · Estimated holding basis $602.22

Q2 2025
Sold 23.6% of the position−809 shares · 2.63K shares remained
Filing context

Quarter-end price $536.34 · Estimated holding basis $535.46

Q1 2025
Sold 61.2% of the position−5.43K shares · 3.43K shares remained
Filing context

Quarter-end price $419.95 · Estimated holding basis $535.46

Portfolio importance

How important is Idexx Labs Inc in Bridgewater Associates, LP’s reported portfolio?

Relative importance is measured only within the verified primary non-option reported portfolio for each quarter.

Current portfolio weight0.1%Q2 2026
Current rank#227of 997 reported positions
Peak portfolio weight0.4%Q4 2021
Best historical rank#46Q4 2021
At peak importanceQ4 2021
IDXX
0.4%
Largest holding
5.2%
Cross-investor discovery

Who else owns Idexx Labs Inc?

Also reported by 2 other tracked investors in their latest verified filings.

Terry SmithFundsmith LLP
IDXX3.9% of reported portfolio
Joel GreenblattGotham Asset Management
IDXX0.1% of reported portfolio
Explore Idexx Labs Inc across all tracked investors →
SEC evidence & methodology

SEC filing evidence

Market context and filing-derived values are kept separate from actual transaction prices, which 13F filings do not disclose.

Latest verified stock price$511.652026-09-18

Market context only; not an investor transaction price.

Latest filing quarter-end price$526.44Q2 2026

Derived from validated reported value and shares where supported.

Estimated holding basis$544.75Historical reference — not actual purchase price

Calculated from supported filing history.

Latest verified investor filingQ2 2026 · filed 2026-08-14
Open SEC filing ↗

This tracker follows Bridgewater Associates, LP’s Form 13F disclosures, not Ray Dalio’s personal brokerage account. Form 13F reports quarter-end positions later and does not reveal exact trade dates or execution prices.